Passive protective effect of chicken egg yolk immunoglobulins against experimental enterotoxigenic Escherichia coli infection in neonatal piglets

Abstract

Passive protection of neonatal piglets against fatal enteric colibacillosis was achieved with powder preparations of specific antibodies against K88, K99, and 987P fimbrial adhesins of enterotoxigenic Escherichia coil. The antibody powders were obtained by spray drying the water-soluble protein fraction of egg yolks from immunized hens after the lipid components were precipitated with an aqueous dispersion of acrylic resins (Eudragit L3OD-55; Rohm pharma). The anti-K88,-K99, and-987P antibody preparations reacted specifically against the corresponding fimbrial antigens in an enzyme-linked immunosorbent assay. The orally administered antibodies protected in a dose-dependent fashion against infection with each of the three homologous strains of E. coli in passive immunization trials with a colostrum-deprived piglet model of enterotoxigenic E. coli diarrhea. Scanning electron microscopy revealed adherence of enterotoxigenic E. coli in intestinal epithelial surfaces of control piglets, whereas in treated piglets treated with high-titer antibodies, a resistance to bacterial adhesion was observed. An enzyme immunoassay with avidin-biotin complex demonstrated specific local antibody activity in target areas of the small intestines. In vitro, E. coli K88+, K99+, and 987P+ strains adhered equally to porcine duodenal and ileal epithelial cells but failed to do so in the presence of homologous anti-fimbrial antibodies. Absorption of egg yolk antibodies with fimbrial immunosorbent removed the anti-fimbrial antibody fraction and reduced significantly the protective nature of the antibody preparation in a passive immunization experiment, suggesting that anti-fimbrial antibodies were the active components. MATERUILS AND METHODS Animals. A total of 76 colostrum-deprived, newborn Large White pigs were utilized in protection trials with antibody 998 Vol. 60, No. 3 on September 4, 2020 by guest http://iai.asm.org/ Downloaded from PROTECTIVE EFFECT OF CHICKEN EGG YOLK ANTIBODIES 999 powder preparations and absorbed antibody solutions. Fivemonth-old White Leghorn chickens (strain Hyline W36) were utilized for immunization, and New Zealand White rabbits (3 kg) and Japanese Black cattle (4 years old) were used for antiserum production. Bacteria and cultivation conditions. ETEC strains 19304

The Use of Bovine Serum Protein as an Oral Support Therapy Following Coronavirus Challenge in Calves

“…In contrast to the current study and that reported by Quigley and Drew (2000), these calves began consuming the anti-rotavirus colostrum at birth, thereby allowing some Ig absorption. Similarly, newborn pigs were protected against E. coli challenge-induced diarrhea when orally dosed with egg yolk-based antibody solutions obtained from immunized hens (Yokoyama et al, 1992). The bovine-serum material used in the current study was not tested for titers against BCV.…”

A new membrane based process to isolate immunoglobulin from chicken egg yolk

“…Presently, IgY has been used extensively for prevention and treatment of various infections in animals and humans with mixed success (Hamada & Kodama, 1996). Other potential uses of IgY in immunotherapy and immunodiagnostics has been reported by many authors (Ambrosius & Hadge, 1987;Larsson & Sjoquist, 1988;Otake et al, 1991;Yokohama et al, 1992).…”

Application of chicken egg yolk immunoglobulins in the control of terrestrial and aquatic animal diseases: A review

“…IgY has been orally administered to piglets and offers a potential prophylactic and therapeutic approach for controlling E. coli-induced diarrhea. Yokoyama et al (1992) showed that orally administered IgY generated against E. coli K88, K99, or 987P fimbriae was protective against infection from each of the three homologous strains of E. coli in a dose-dependent manner. E. coli K88, K99, and 987P strains adhered equally to porcine epithelial cells from the duodenum and ileum but failed to so in the presence of homologous anti-fimbrial IgY.…”